Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
BBVA Argentina
BBAR
$3.18B
| $920K | ﹤0.01% |
165,182
-74,682
| -31% | -$308K |
|
2677
OneSpaWorld
OSW
$2.72B
| $916K | ﹤0.01% |
+54,400
| New | +$856K |
|
|
IMBI
2678
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
| $916K | ﹤0.01% |
229,496
+16,415
| +8% | +$85.1K |
|
2679
BGC Group
BGC
$5.22B
| $912K | ﹤0.01% |
153,548
-1,056,216
| -87% | -$5.96M |
|
|
CEQP
2680
DELISTED
Crestwood Equity Partners LP
CEQP
| $911K | ﹤0.01% |
29,556
+17,274
| +141% | +$569K |
|
2681
Vanguard Consumer Discretionary ETF
VCR
$6.1B
| $910K | ﹤0.01% |
+4,800
| New | +$878K |
|
|
FARO
2682
DELISTED
Faro Technologies
FARO
| $903K | ﹤0.01% |
+17,942
| New | +$877K |
|
2683
Commercial Metals
CMC
$7.97B
| $900K | ﹤0.01% |
+40,400
| New | +$818K |
|
|
FSFG
2684
DELISTED
First Savings Financial Group
FSFG
| $899K | ﹤0.01% |
40,200
+6,300
| +19% | +$136K |
|
|
SYRS
2685
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $892K | ﹤0.01% |
12,909
-15,751
| -55% | -$955K |
|
|
ARGO
2686
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $892K | ﹤0.01% |
13,565
-25,100
| -65% | -$1.64M |
|
|
LBY
2687
DELISTED
Libbey, Inc.
LBY
| $891K | ﹤0.01% |
614,800
+105,100
| +21% | +$197K |
|
2688
AMREP Corp
AXR
$121M
| $885K | ﹤0.01% |
147,980
+15,700
| +12% | +$92K |
|
|
RLH
2689
DELISTED
Red Lions Hotel Corporation
RLH
| $882K | ﹤0.01% |
236,490
-102,200
| -30% | -$477K |
|
2690
Scully Royalty
SRL
$89.8M
| $880K | ﹤0.01% |
71,006
+4,236
| +6% | +$46.6K |
|
2691
Akebia Therapeutics
AKBA
$241M
| $875K | ﹤0.01% |
138,527
+95,100
| +219% | +$452K |
|
2692
Vanguard S&P 500 Growth ETF
VOOG
$27.3B
| $872K | ﹤0.01% |
+30,000
| New | +$833K |
|
|
PW
2693
Power REIT
PW
$2.93M
| $869K | ﹤0.01% |
9,656
+1,022
| +12% | +$90.5K |
|
|
KAMN
2694
DELISTED
Kaman Corp
KAMN
| $865K | ﹤0.01% |
13,122
-55,000
| -81% | -$3.44M |
|
|
CYRN
2695
DELISTED
CYREN Ltd.
CYRN
| $865K | ﹤0.01% |
33,771
+1,206
| +4% | +$36.3K |
|
|
KDMN
2696
DELISTED
Kadmon Holdings, Inc.
KDMN
| $864K | ﹤0.01% |
+190,800
| New | +$698K |
|
|
NINE
2697
DELISTED
Nine Energy Service
NINE
| $862K | ﹤0.01% |
110,200
+47,800
| +77% | +$278K |
|
|
OBSV
2698
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $856K | ﹤0.01% |
224,100
+136,100
| +155% | +$707K |
|
2699
Liberty Broadband Class C
LBRDK
$5.29B
| $855K | ﹤0.01% |
+6,800
| New | +$792K |
|
2700
Puma Biotechnology
PBYI
$444M
| $853K | ﹤0.01% |
+97,500
| New | +$807K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.